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Abstract
A simple deterministic model is proposed to represent the ba-
sic aspects concerning the effects of different antiretroviral treatment
schedulles on HIV incidence and prevalence of affected populations.
The model mimics current treatment guidelines applied in Brazil.
However, the model does not intend to fit the data with any acceptable
degree of accuracy since uncertainties on the values of the parameters
and on the precise effect of the treatment put some limits on the prac-
tical implications of our model from which only orders of magnitude
and some qualitative effects can be deduced. So, this paper intends to
provide a conceptual and mechanistic understanding of the possible
long term effects of treatment on the dynamics of HIV transmission.
According to the model, the effect of the treatment depends on the
level of sexual activity of the subpopulations considered, being more
pronounced on the subpopulations with the highest sexual activity
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levels. Also, inefficient treatment can be prejudicial depending on
the level of sexual activity and on the capacity to provide adequate
treatment coverages to the population affected.
1 Introduction
The natural history of the Human Immunodeficiency Virus (HIV) infection
and transmission is well understood today. It is now accepted that the viral
concentration in the circulating blood (viraemia) and other organic fluids
determines the probability of transmission [1]. It has been demonstrated by
several authors that after infection the viraemia rapidly increases in the first
week to a high level, staying in that high levels for some weeks, dropping
afterwards to very low levels and then increasing slowly for several years.
After a period of 10 - 15 years, the increasing level of viraemia reaches a level
in which clinical manifestations begin, coinciding with the dropping in the
CD4 lymphocytes (the target cell of HIV) counting and the development of
the conditions that define the state of full-blown AIDS.
So, it should be expected a large variation in the probability of transmis-
sion of HIV along the natural course of the infection [2]. The relative con-
tribution of each of these distinct phases of viraemia seen along the natural
history of the infection to HIV transmission have only recently been demon-
strated [3]. This relative contribution may have important consequences to
the epidemiological pattern of HIV transmission, as well as to the assess-
ment of the impact of HIV treatment on the epidemiology of HIV/AIDS. In
addition, it should be expected that differences in the probability of transmis-
sion in each of the distinct phases of the infection may also have important
consequences on the evolution of HIV virulence [4].
The use of the combined antiretrovirus therapies (ARVTs), particularly
those known as HAART (highly active antiretrovirus therapies) has demon-
strated excellent results in all the countries where people infected by HIV
has access to the treatment [5]. The results reported significant reduction in
deaths rates caused by opportunistic infections. For example, in the U.S.A.
there has been a reduction of 61% between 1995 and 1997 in the mortality
due to AIDS. In Brazil, whose experience has been acclaimed worldwide as
one of the most successful attempts to control AIDS, the government de-
cided to provide ARVT to all HIV seropositive individuals who fulfilled the
treatment criteria. From 1996 onwards HAART has been used as a standard
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treatment, with 120,000 patients being treated in 2002.
The treatment against HIV evolved rather rapidly. Just 4 years after the
identification of HIV as the causative agent of the new syndrome, AIDS, zi-
dovudine (AZT) the first drug for its treatment was licenced by the FDA. In
the next eight years three other nucleoside analogs (the same class as zidovu-
dine) were introduced. Concurrently, a better understanding of the dynam-
ics of HIV replication and drug resistance mechanisms caused a shift from
single- to combination-drug therapy. From 1995 to 1998 eight new antiretro-
viral agents were approved, including protease inhibitors and non-nucleosides
transcriptase inhibitors . These latter drugs also provided clinicians with a
highly effective antiretroviral therapy, known as HAART that reduces viral
load by a factor of 103. However, these new drugs cause several important
side effects that limit their use. Because of this, current clinical guidelines
propose a delaying in starting HIV treatment to a point in which either
the viral load is high (above 30000 copies per ml) or the CD4 cell count is
low. However, with the progression of the infection, even in the persistence
of treatment, HIV viral load tends to increase again leading to a need to
change the drugs in use or to progression to AIDS [6].
The discussion on the implications of antiretroviral antiretroviral treat-
ment has been restricted to clinical and virological aspects. However, con-
sidering that different antiretroviral treatment strategies have distinct effects
on viral load, one crucial aspect to be considered is the epidemiological con-
sequences of a given antiretroviral treatment strategy on the incidence of
new HIV infections. On one hand, effective antiretroviral treatment reduces
viral load. On the other hand, it prolongs the asymptomatic phase, proba-
bly the most important for transmission [3] in the absence of antiretroviral
treatment. Both effects are intrinsically related to transmission, although in
opposite directions. Therefore, the critical question related to the choice of
the best antiretroviral strategy should take into account the epidemiological
consequences of different antiretroviral treatments. In spite of some attempts
to understand this crucial aspect, the best antiretroviral treatment strategy
is still to be defined [7],[8], [9].
In this paper we propose a schematic mathematical model to analyze the
impact of current antiretroviral therapy on the incidence and prevalence of
HIV infection. In section 2, we point out some historical aspects of Brazilian
public health strategies related to HIV/AIDS treatment and its impact on the
epidemics in Brazil. Our model was constructed incorporating the treatment
concepts of the Brazilian program. However, due to uncertainties in param-
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eters, practical conclusions should be taken with caution. In section 3, we
derive an integral equation which allows the calculation of the impact on HIV
incidence of an antiretroviral treatment program. This equation depends on
a number of functions and parameters whose forms and values are described
in section 4. In section 5, we present numerical results of several hypothetical
scenarios and in section 6 we discuss the model´s limitations and draw some
tentative conclusions regarding possible epidemiological implications of our
results.
2 Motivation: the Brazilian experience with
HAART
Since 1991 the Brazilian government decided to provide ARVT to all HIV
seropositive individuals who fulfilled the treatment criteria [10]. From 1996
onwards HAART has been used as a standard treatment, with 120,000 pa-
tients being treated in 2002. Its impact was immediately noted by health
authorities, in particular its dramatic reduction on AIDS mortality, and this
public health experience has been acclaimed worldwide as one of the most
successful attempts to control AIDS.
Figure 1 shows the reduction in the mortality by AIDS in the period
between 1996 and 2001. The total number of averted deaths summed up to
90,000 patients in this period.
Figure 1
In addition, it was observed an increase in the survival period of patients
with AIDS, from 5 to 58 months, a 12 fold increase, after the introduction
of HAART treatment. Also, there was a six-fold reduction in the number of
AIDS hospitalizations and a reduction of 54% in the cost of treatment.
With respect to the impact of HAART on the incidence and prevalence
of HIV infection, only rough estimates are available. For instance, in 1992
the World Bank projected the number of expected HIV infected individuals
in Brazil by 2002 as 1.2 million. However, the current estimates for 2002
is around 600 thousands. It is difficult to attribute this reduction solely
to HAART, since other preventive practices have been highly stimulated
by the Brazilian government. For instance, the observed reduction in HIV
infection prevalence among sex workers from 18% in 1996 to 6.1% in 2000, and
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among homosexuals from 10.8% in 1999 to 4.7% in 2001, has been attributed
by health authorities to the association of condom distribution and other
preventive measures adopted.
The most important indication of the possible impact of HAART on HIV
transmission in Brazil is the marked reduction in incidence rates of AIDS,
as shown in figure 2. It is noticeable that after a historical increase in the
incidences from 8 cases per 100,000 people per year in 1991 up to the peak
of 18 cases per 100,000 people per year attained in 1998, the number of new
cases dropped to 5 cases per 100,000 people per year in 2003. If we consider
that the universal treatment started in 1996, we may conclude that after a
delay of two years, the effect of HAART on the incidence of AIDS could be
observed.
Figure 2
Notwithstanding, the observed reduction in HIV incidence and prevalence
cannot be entirely explained by the effects due to HAART. Additionally,
behavioral changes attributable to the preventive campaigns carried out in
Brazil simultaneously to the beginning of HAART may also have had a pos-
itive impact on HIV transmission. For instance, there have been a marked
increase in regular condom use verified between 1999 and 2000 (42% to 64%).
The Brazilian experience motivated us to model the possible role of ARVT
on the incidence and prevalence of HIV. However, lack of data and uncertain-
ties on the precise effect of the treatment put some limits on the practical
implications of our model from which only orders of magnitude and some
qualitative effects can be deduced.
3 The model: formalism
3.1 Sexually transmitted HIV
As in previous papers, we consider a community of N individuals in steady
state with respect to time [3], divided into classes according to the contact
pattern and transmission intensity of HIV [11]. For simplicity, in this paper
we consider that the interaction between individuals from different classes
is so rare that can be neglected. The classes will be described in section 5.
As the interclass interactions are neglected, we describe a general formalism
which applies to any and all classes.
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Let N(a)da be the number of individuals with age between a and a+ da.
Among those, let X(a)da be the number of susceptibles with age between a
and a+ da. The number of unprotected sexual contacts per unit time those
individuals with age between a and a + da make with all other individuals
with ages between a′ and a′ + da′ is:
β0(a, a
′)da′X(a)da (1)
Let Y1(a
′, τ )da′dτ be the number of individuals with age between a′ and
a′+da′ infected when aged between τ and τ+dτ . The number of unprotected
sexual contacts per unit time those individuals with age between a and a+da
make with all other individuals with ages between a′ and a′ + da′ is
β0(a, a
′)da′
Y1(a
′, τ)da′dτ
N(a′)da′
X(a)da (2)
Let g(a′− τ ) be the probability of a susceptible individual to get infected
when making an unprotected sexual contact with an individual Y1(a
′, τ)da′dτ .
This depends on viral load which in turn depends on the time since infection
(a′− τ ), and its form is given by equation (33) Therefore, the number of new
infections per unit time, due to individuals Y1(a
′, τ)da′dτ , is given by
β0(a, a
′)g(a′ − τ)Y1(a
′, τ )
N(a′)
da′dτX(a)da (3)
Let Y2(a
′, τ , l)da′dτdl be the number of individuals with age between a′
and a′+da′ infected when aged between τ and τ+dτ and treated continuously
after l, that is, the treatment is initiated between l and l + dl. Therefore,
the fraction of the unprotected sexual contacts given by equation (1), with
individuals with age a′ and a′+da′ infected when aged between τ and τ +dτ
and treated between l and l + dl is
β0(a, a
′)da′
Y2(a
′, τ , l)da′dτdl
N(a′)da′
X(a)da (4)
Note that we assumed that the sexual behavior of susceptible towards
treated and untreated infected individuals is the same.
Let g1(a
′− l, l−τ ) be the probability of a susceptible individual to get in-
fected when making an unprotected sexual contact with a treated individual
Y2(a
′, τ , l)da′dτdl. This depends on viral load which in turn depends on the
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time since infection (a′−τ ) and the time since the start of the treatment, and
its form is given by equation (38). Therefore, the number of new infections
per unit time, due to treated individuals Y2(a
′, τ , l)da′dτdl, is given by
β0(a, a
′)g1(a
′ − l, l − τ )Y2(a
′, τ , l)
N(a′)
da′dτdlX(a)da (5)
After integrating equation (3) from 0 to a′ with respect to τ , and from 0
to infinite with respect to a′, and integrating (5) from τ to a′ with respect to
l, from 0 to a′ with respect to τ , and from 0 to infinity, with respect to a′,
and summing the two contributions, we get the so-called per capita force of
infection, λ(a), defined as
λ(a) =
∫
∞
0
∫ a′
0 β0(a, a
′)g(a′ − τ)Y1(a′,τ)
N(a′)
dτda′
+
∫
∞
0
∫ a′
0
∫ a′
τ β0(a, a
′)g1(a
′ − l, l − τ )Y2(a′,τ ,l)
N(a′)
dldτda′
(6)
As we showed in a previous paper [12], the contact function β0(a, a
′) must
satisfy a symmetry relation. To see this, let
β0(a, a
′)da′N(a)da (7)
be the number of unprotected sexual contacts individuals with age between
a and a + da make with all individuals aged between a′ and a′ + da′. This
number should be equal to the number of unprotected sexual contacts that
individuals aged between a′ and a′ + da′ make with all individuals with age
between a and a+ da,
β0(a
′, a)daN(a′)da′ (8)
that is,
β0(a, a
′)
N(a′)
=
β0(a
′, a)
N(a)
(9)
This can be satisfied if β0(a, a
′) is of the form
β0(a, a
′) = f(a, a′)
N(a′)
N
(10)
where N =
∫
∞
0 N(a)da is the total population and f(a, a
′) is a symmetric
function of a and a′, describing the per capita rate of unprotected sexual
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contacts(see equations 29 and 30). Note that, due to the division by popula-
tion size an increase in the frequency of age groups entirely uninterested for
a given person will decrease his/hers sexual activity with those specific age
groups. However, this is reflected automatically in the form of f(a, a′).
Substituting (10) in (6) we get
λ(a) =
1
N
∫
∞
0
∫ a′
0
f(a, a′)g(a′ − τ )Y1(a′, τ)dτda′
+
1
N
∫
∞
0
∫ a′
0
∫ a′
τ
f(a, a′)g1(a
′ − l, l − τ)
Y2(a
′, τ , l)dldτda′ (11)
Now, the equation for X(a) is
dX(a)
da
= −λ(a)X(a)− µX(a) (12)
where µ is the natural mortality rate of humans.
Equation (12) can be integrated, resulting in
X(a) = X (0) exp
[
−
∫ a
0
λ(s)ds− µa
]
. (13)
Let us define h1 (a, τ ) as a function describing the removal of individuals
from the first infective condition by natural mortality and additional mortal-
ity due to progression to AIDS (see equation 35), and h2 (a, τ) describing the
removal by antiretroviral treatment (see equation 37). Then we can write:
Y1(a, τ) = Y1(τ , τ)h1 (a, τ) h2 (a, τ) (14)
Now we have:
Y1(a, a) = λ(a)X(a) (15)
Substituting equation (13) in (15), we have:
Y1(a, a) = X(0)λ(a) exp
[
−
∫ a
0
λ(s)ds− µa
]
(16)
Substituting (16) in (14) we get
Y1(a, τ ) = X(0)λ(τ) exp
[
−
∫ τ
0
λ(s)ds− µτ
]
h1 (a, τ) h2 (a, τ) (17)
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Substituting equation (17) in (11) we get:
λ(a) =
X(0)
N
∫
∞
0
∫ a′
0
f(a, a′)g(a′ − τ)
λ(τ )e[−
∫
τ
0
λ(s)ds−µτ]h1 (a
′, τ )h2 (a
′, τ) dτda′
+
1
N
∫
∞
0
∫ a′
0
∫ a′
τ
f(a, a′)
g1(a
′ − l, l − τ)Y2(a′, τ , l)dldτda′ (18)
Assuming a antiretroviral treatment rate ν (τ , a), we have
Y2(l, τ , l) = Y1(l, τ)ν (τ , l) (19)
and
Y2(a, τ , l) = Y2(l, τ , l)h3 (a, τ , l) (20)
where h3 (a, τ , l) is a function describing the removal of individuals from the
treated condition by mortality (see equation 39 below). Then, substituting
equations (17) in (19) and the resulting equation in equation (20), we get
Y2(a, τ , l) = X(0)λ(τ ) exp
[
−
∫ τ
0
λ(s)ds− µτ
]
h1 (l, τ )h2 (l, τ )h3 (a, τ , l) ν (τ , l) (21)
so that we have
λ(a) =
X(0)
N
∫
∞
0
∫ a′
0
λ(τ)e−
∫
τ
0
λ(s)ds−µτ
f(a, a′)g(a′ − τ)h1 (a′, τ)h2 (a′, τ) dτda′
+
X(0)
N
∫
∞
0
∫ a′
0
∫ a′
τ
ν (τ , l) h1 (l, τ) h2 (l, τ) h3 (a
′, τ , l)
f(a, a′)g1(a
′ − l, l − τ )dldτda′ (22)
Equation (22) always has λ(a) = 0 as a solution. Depending on the
functions f(a, a′)g(a′ − τ ), f(a, a′)g1(a′ − l, l − τ ) and on the parameters of
f(a, a′)g(a′ − τ), f(a, a′)g1(a′ − l, l − τ ), h1 (a′, τ), h2 (a′, τ ), h3 (a′, τ , l) and
ν (τ , l), it may have another unique positive solution [3]. The condition for
equation (22) to have another solution, that is λ(a) 6= 0 defines the threshold
above which the infection can establish itself in the population [13], [14].
If we assume that X(0) is proportional to the total population, X(0) =
bN , where b is a constant, equation (22) becomes independent on the popu-
lation size. In this paper we take b = µ, for simplicity.
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3.2 Parenterally transmitted HIV
In this subsection we model the parenteral transmission of HIV due to shar-
ing contaminated syringes and needles or contaminated blood and blood
products.
We consider that sexual transmission among these individuals is negligible
when compared with the parenterally form of transmission. However, their
contribution to the sexual spread of the infection will be considered in this
section.
Let Y I1 (a
′, τ)da′dτ be the number of individuals parenterally infected with
HIV (PI), aged between a′ and a′ + da′, who acquired the infection when
aged between τ and τ + dτ. We consider that PIs enter this group when
aged a1. We also consider that they form a proportion η of the population.
Calling ξ the rate of sharing syringes (or receiving blood or blood products)
multiplied by the probability of getting the infection if the syringe (or blood
or blood products) is (are) infected, we have:
Y I1 (a
′, τ) = X(0)ηξ exp [−µτ ] exp [−ξ (τ − a1)]
θ (τ − a1)h1(a′, τ)h2(a′, τ ) (23)
where h1(a
′, τ) and h2(a
′, τ) were defined in the previous section and are the
rates of removal from the infective class by death and treatment, respectively.
Note that we have assumed that in the case of drug users, they remain drug
users for the rest of their lives and that their mortality rate is not affected by
the drug addiction. This simplification is partially supported by field work
we carried out in the past [15], when we demonstrated that the average time
of drug usage of the studied community was found to be around 10 years.
Assuming an antiretroviral treatment rate ν (τ , a), we have
Y I2 (l, τ , l) = Y
I
1 (l, τ)ν (τ , l) (24)
and
Y I2 (a, τ , l) = Y
I
2 (l, τ , l)h3 (a, τ , l)
where h3 (a, τ , l) is a function describing the removal of individuals from the
treated condition by mortality. Then, we get
Y I2 (a, τ , l) = h1(a
′, τ)h2(a
′, τ)h3 (a, τ , l) ν (τ , l) (25)
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Dividing equations (23) and (25) by N , and adding to the corresponding
terms in equation (11), we finally get, instead of (17) and (21):
Y1(a, τ ) = X(0) (1− η)λ(τ ) exp
[
−
∫ τ
0
λ(s)ds− µτ
]
h1 (a, τ) h2 (a, τ) + ηX(0)ξ exp [−µτ ]
exp [−ξ (τ − a1)] θ (τ − a1)h1 (a, τ) h2 (a, τ) (26)
and
Y2(a, τ , l) = X(0) (1− η) λ(τ) exp
[
−
∫ τ
0
λ(s)ds− µτ
]
h1 (l, τ) h2 (l, τ )h3 (a, τ , l) ν (τ , l)
+ηX(0)ξ exp [−µτ ] exp [−ξ (τ − a1)]
θ (τ − a1)h1 (l, τ )h2 (l, τ )h3 (a, τ , l) ν (τ , l) (27)
Finally, instead of (22) we get
λ(a) =
X(0)
N
∫
∞
0
∫ a′
0
(1− η)λ(τ )
exp
[
−
∫ τ
0
λ(s)ds− µτ
]
f(a, a′)g(a′ − τ )h1 (a′, τ)
h2 (a
′, τ) dτda′ +
X(0)
N
∫
∞
0
∫ a′
0
η exp [−µτ ]
exp [−ξ (τ − a1)] θ (τ − a1) f(a, a′)g(a′ − τ)
h1 (a
′, τ) h2 (a
′, τ ) dτda′ +
X(0)
N
∫
∞
0
∫ a′
0
(1− η)
λ(τ ) exp
[
−
∫ τ
0
λ(s)ds− µτ
]
f(a, a′)g(a′ − τ)
∫ a′
τ
ν (τ , l)h1 (l, τ )h2 (l, τ )h3 (a
′, τ , l) f(a, a′)
g1(a
′ − l, l − τ)dldτda′ + X(0)
N
∫
∞
0
∫ a′
0
η
exp [−µτ ] exp [−ξ (τ − a1)] θ (τ − a1)∫ a′
τ
ν (τ , l)h1 (l, τ )h2 (l, τ )h3 (a
′, τ , l)
f(a, a′)g1(a
′ − l, l − τ)dldτda′ (28)
As mentioned before, if we assume that X(0) is proportional to the pop-
ulation, for instance, X(0) = µN , the equation (28) becomes independent of
the population size.
11
4 A schematic model
In this section we propose forms for the different functions involved in equa-
tion (28).
Let us begin with an untreated population, for which ν(τ , l) = 0 and
h2(a
′, τ) = 1 so that the second part of the integral equation (28) vanishes.
As in [3], let us define the rate f(a, a′), in a very schematic form:
f(a, a′) = f0(a, a
′)θ(a− a0)θ(a′ − a0) (29)
where f0(a, a
′) is the rate of unprotected sexual contacts and a0 is the age at
which individuals enter in the risk behavior group. The Heaviside functions
θ(a− a0) and θ(a′ − a0) mean that sexual activity begins after age a0.
For the function f0(a, a
′), which describes the age preferences in acquisi-
tion of new partners and the age decline in the sexual activity, we propose:
f0(a, a
′) = Qβ3(a)β3(a
′)β4(a− a′) (30)
where
β3(x) =
1√
2piσ1
e
−
(x−M)2
σ2
1 (31)
and
β4(a− a′) =
1√
2piσ2
e
−
(a−a′)2
σ2
2 (32)
The parameter M is the age of maximum sexual activity and the constant
Q is adjusted to give the assumed average number of unprotected sexual
contacts per unit time. Those forms for the β-functions (31) and (32) were
chosen for convenience only and, although not supported by social studies,
they conform with the following facts: a) sexual activity increases with age up
to a maximum, decreasing thereafter; b) age preferences of an individual are
distributed around a maximum value which we assumed to occur at the same
age of the individual. In order to facilitate the calculations we made both
functions as symmetric around a central value and we assumed a minimum
age a0, below which there is no sexual activity. In addition we assumed that
people without treatment, people undergoing treatment, and even people
with full blown AIDS have the same sexual behavior. This assumption is
supported by preliminary data in our community of HIV patients (Bueno,
personal communication).
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Let ANT (a′ − τ ) be the viraemia level of non-treated individuals which
depends on the time interval since the infection. For g(a′ − τ ) we take the
form
g(a′ − τ) = I(ANT (a′ − τ)) (33)
where I(ANT ) is a function representing the transmission of at least one
infective viral inocula, given the viremic level ANT . As in [3] we assume that
I
(
ANT
)
= (c′ + c′′ logANT )θ
(
logANT − 3
)
(34)
where c′ = −3.35 × 10−3 and c′′ = 1.2 ×10−3are parameters obtained by
fitting equation (34) to the data by Gray et al. [20] (an almost identical
relationship between log of viral load and transmissibility was found by using
data from Vella et al [17] and Garcia et al [18], and it is supported by the
observations of Fideli et al.[19] and Quin et al. [16]). The Heaviside function
θ
(
logANT − 3
)
is such that if logANT ≤ 3 there is no transmission.
For the removal of infected individuals, we assumed that when (a′ − τ) <
Lc, where Lc is a given critical moment when individuals reach a certain
viraemia level and are defined as AIDS patients, dies with rate µ. When
(a′ − τ) > Lc, individuals are subjected to an additional, disease specific,
death rate, α. A simple form for this removal function is:
h1 (a
′, τ) = e−µ(a
′
−τ)θ (Lc − (a′ − τ ))
+e−µ(a
′
−τ)−α((a′−τ)−Lc)θ ((a′ − τ)− Lc) (35)
Let us now consider the treated population. The variables and parameters
already defined for the untreated population remain the same. We must only
define values for h2(a
′, τ), ν(τ , l), g1(a
′ − l, l − τ) and h3(a′, τ , l), where l is
the moment in the history of the infection at which individuals begin to be
treated.
Let AT (a′−l, l−τ ) denote the viraemia level after antiretroviral treatment.
We assumed that the viraemia level after antiretroviral treatment is reduced
by a certain factor, ∆(l − τ ), increasing thereafter as
AT (a′ − l, l − τ ) = A
NT (l − τ)Ψ(a′ − l)
∆(l − τ) (36)
where Ψ(a′− l) is a given function with Ψ(0) = 1. Note that with such func-
tions, the log of the viraemia level just after the beginning of the antiretrovi-
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ral treatment starts with log
[
ANT (l − τ )
]
− log [∆(l − τ)] and increases with
log [Ψ(a′ − l)] thereafter.
Figure 3a schematically illustrates the natural history of HIV infection
in the absence of antiretroviral treatment. Figure 3b illustrates the effect of
antiretroviral treatment on the viraemia level.
Figure 3a
Figure 3b
In Figure 3a the viraemia level reaches a maximum immediately after the
moment τ of the infection and drops rapidly after some few weeks, probably
due to the effect of the immune system. Viraemia then starts to raise, and
simultaneously a decrease in the counting of CD4 T-lymphocytes is observed,
until a critical viral load level is reached (Lc), when the immune system breaks
down and full blown AIDS develops. This period lasts for 10 - 15 years.
Figure 3b represents the assumed natural history of HIV infection in the
presence of antiretroviral treatment, which begins at the age of infection be-
tween l and l + dl. The treatment starts at any moment after the viral load
reaches 30,000 copies/ml [21](we are well aware, however, that in real life
other clinical indicators of antiretroviral treatment, like CD4 counting, are
used to begin the antiretroviral treatment.). We assumed that the treat-
ment causes a sharp decrease in the viral load, and that it loses its effect
immediately so that the viral load starts to rise log-linearly again. This in-
tends to model the appearance of resistant strains, which we assumed to
have the same virulence as the original strain. Therefore, the assumption
of log-linearity in the viral load curve is entirely hypothetical and was in-
tended to mimic an immediate development of full resistance by HIV to the
treatment , which is the worst epidemiological scenario. In this situation, we
are assuming that replication of HIV is no longer constrained by treatment.
Another assumption of our model is that it takes no account of the role of
the immunity system on HIV replication. With the above assumptions, the
viral load after treatment increases until a critical level is eventually reached
(L′c), when the immune system breaks down and full blown AIDS develops.
Hence, the treatment makes the period without AIDS longer than 10 years.
We assumed also that the antiretroviral treatment schedule is given by
ν(τ , l) = ν × θ ((l − τ)− at), and it begins, as mentioned above, when vi-
raemia reaches 30,000 copies/ml, which occurs at the infection age (l−τ ) = at
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(≃ 6.7 years). Thus
h2(l, τ) = e
−ν×((l−τ)−at)×θ((l−τ)−at) . (37)
Since we assume that the treatment affects only the viral load, we may
define g1(a
′ − l, l − τ) as:
g1(a
′ − l, l − τ ) = I
(
AT (a′ − l, l − τ )
)
(38)
Finally, for h3(a, τ , l) we may also assume a simple form, similar to
h1 (a
′ − τ ):
h3(a
′, τ , l) = h3(a
′, l) = e−µ(a
′
−l)θ (L′c − (a′ − l))
+e−µ(a
′
−l)−δ((a′−l)−L′c)θ ((a′ − l)− L′c) (39)
where L′c is the new critical moment when treated individuals reach a certain
viraemia level and are defined again as AIDS patients. Those patients are
subjected to a new differential mortality rate δ due to AIDS.
Within this framework we can obtain different particular models by choos-
ing suitable functions ANT , AT and constants.
We adopted, for the non-treated patients, the following average values for
Ai and Li:
ANT (a′ − τ) =


A1(a
′ − τ) = 106
for 0 ≤ (a′ − τ ) < L1
A2(a
′ − τ) = 103+0.22(a′−τ−L1)
for L1 ≤ (a′ − τ ) < Lc
A3(a
′ − τ) = 106
for (a′ − τ) ≥ Lc
(40)
where L1 = 6 weeks and Lc − L1 = 30.22 years is the period of time it takes
for the viraemia to reach 106RNA copies per ml since the beginning of the
second phase.
Let us now model the effectiveness of antiretroviral treatment by an in-
stantaneous reduction on the viral load immediately after the introduction of
the treatment. We consider several effectiveness levels of antiretroviral treat-
ment, by varying the reduction of the viral load. When the reduction is by
a factor greater than 102, the antiretroviral treatment is known as HAART
(Highly Active AntiRetroviral Treatment). If the reduction is lesser than 102,
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the antiretroviral treatment is known as non-HAART. Again, for the sake of
simplicity, we drop the superscript T from the viral load A and introduce a
subscript j = 4, 5, describing the two possible phases of the natural history
of the infection after treatment. Note that we assumed no treatment during
the first phase.
AT ((a′ − l), (l − τ )) =

A4((a
′ − l), (l − τ)) = 103−K+0.22(l−τ−L1)+0.22(a′−l)
for 0 ≤ (a′ − l) < L′c
A5((a
′ − l), (l − τ)) = 106
for (a′ − l) ≥ L′c
(41)
where L′c =
3+K−0.22(l−τ−L1)
0.22
years, so that Ψ(a′ − l) = 100.22(a′−l) , similar to
the non-treated patients, and ∆(l − τ ) = K ≥ 2 for HAART treatment and
∆(l − τ) = K < 2 for non-HAART treatment. In the numerical simulations
several values of K will be considered. Note that L′c is the period of time it
takes for the viraemia of treated individuals to reach 106RNA copies per ml
since the beginning of antiretroviral treatment.
With the above models of viraemia, g(a′ − τ) takes the form
g(a′ − τ ) =


I(A1((a
′ − τ))) for 0 ≤ (a′ − τ) < L1
I(A2((a
′ − τ))) for L1 ≤ (a′ − τ ) < Lc
I(A3((a
′ − τ))) for (a′ − τ ) ≥ Lc
, (42)
where I(A1) is a function defined by equation (34), representing the proba-
bility of transmission of at least one infective viral inocula. Correspondingly,
g1(a
′ − l, τ ) takes the form
g1(a
′ − l, l − τ) =


I(A4((a
′ − l), (l − τ)))
for 0 ≤ (a′ − l) < L′c
I(A5((a
′ − l), (l − τ)))
for (a′ − l) ≥ L′c
(43)
Finally, for the parenterally transmitted branch of the infection we take
η = 0.01, ξ = 0.05 per year and a1 = 15 years [15], [22].
5 Numerical results
In order to analyze the model’s performance against an HIV endemic situa-
tion we solved equation (28) numerically for several treatment schedules. For
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this we divided the population into four classes. Each class obeys an equation
like equation (28) and intends to mimic a specific risk group, namely, group I
(GI), with very low level of sexual promiscuity (84% of the total population),
group II (GII) with moderate levels of sexual promiscuity (10%), group III
(GIII) with high levels of sexual promiscuity (5%), and group IV (GIV) with
very high levels of sexual promiscuity (1%). This somewhat arbitrary divi-
sion is based on the actual classes of risk recognizable in real populations.
So GI could represent the general population , GII promiscuous heterosex-
uals, GIII male homosexuals, and GIV commercial sex workers and their
clients.We also assume that in each class there is a fraction η of PIs, who got
infected by contaminated syringes/needles or blood/blood products. With
respect to sexual contacts, it should be stressed that we are only interested
in unprotected sexual contacts with new partners. In the functions β3 and
β4, which describe the sexual behavior, we set, for all classes, σ1 = 10 years,
σ2 = 15 years, M = 25 years. The mortality (and fertility) rate was taken
µ = 1/70 years−1. The initial age of sexual life a0 was set to 15 years.
The parameter Q is related, in the absence of the infection, to the per
capita number of unprotected sexual contacts. We can, then, calculate the
per capita number of unprotected sexual contacts in the population, Φ, as
Φ =
1
N
∫
∞
0
∫
∞
0
β(a, a′)N(a)da′da
= µ
∫
∞
0
∫
∞
0
f0(a, a
′)
N
θ(a− a0)θ(a′ − a0)N(a′)e−µada′da (44)
using equation (29). Using equation (30) we get the relation between the per
capita number of unprotected sexual contacts in the absence of infection, Φ,
and Q:
Φ = µ2Q
∫
∞
a0
∫
∞
a0
β3(a)β3(a
′)β4(a− a′)e−µa
′
e−µada′da (45)
The parameter Q was adjusted to give the estimated average number of
unprotected sexual contacts per unit time, Φ. The results, compatible with
the literature, for each class were Q = 6 × 106 (GI), Q = 1.38 × 107 (GII),
Q = 1.45× 107 (GIII), Q = 1.55× 107 (GIV), as can be seen in table 1.
With respect to the PI arm of transmission, as mentioned above, we chose
the parameters a1 = 15 years, η = 0.001 and ξ = 0.05/year.
Now, in the presence of HIV infection, without any treatment, the inci-
dence of sexually transmitted HIV (i) is defined as the number of new cases
of HIV infection per year per person and was calculated as
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i =
(1− η) [∫∞0 λ(a)X(a)da]
N
(46)
and the incidence of parenterally transmitted HIV (iI) is also defined as the
number of new cases of HIV infection per year per person and was calculated
as
iI = ηµξ
∫
∞
0
exp [−µa] exp [−ξ(a− a1] θ(a− a1)da (47)
With the adopted parameters a1 = 15 years, η = 0.001 and ξ = 0.05 per
year, we have iI = 9× 10−6 per person-year.
The prevalence of sexually transmitted HIV (p) in the absence of treat-
ment is given by
p =
∫
∞
0
∫ a
0
y1(a, τ)dτda (48)
where
y1(a, τ ) =
Y1(a, τ)
N
(49)
where Y1(a, τ ) is given by equation (26) and λ(a) given by equation (28), with
ν(τ , l) = 0 and h2(a
′, τ) = 1. The prevalence of parenterally transmitted HIV
(pI), without treatment, is given by
pI =
∫
∞
0
∫ a
0
ηµξ exp [−µτ ]
exp [−ξ (τ − a1)] θ (τ − a1) h1(a, τ)dτda. (50)
With the adopted parameters a1 = 15 years, η = 0.001 and ξ = 0.05/year,
we have pI = 5.9× 10−4.
The results of the simulation for the per capita number of unprotected
sexual contacts, the prevalence and the incidence of HIV infection at equi-
librium are given in table 1:
Table 1: prevalence and incidence of HIV infection at equilibrium
without PI with PI
class(%) Φ(years−1) incidence prevalence incidence prevalence
GI(84%) 6.60 [24] 0.00 0.00 8.51E-05 1.25E-03
GII(84%) 15.30 [25] 7.09E-04 1.08E-02 1.20E-03 1.89E-02
GIII(84%) 16.00 [26] 2.60E-03 4.50E-02 2.75E-03 4.77E-02
GIV(84%) 17.10 [27] 4.60E-03 9.00E-02 4.63E-03 9.17E-02
Average(84%) 13.20 2.47E-04 4.23E-03 3.75E-04 6.24E-03
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The scenario presented in table 1 is not intended to fit real data but rather
to present qualitatively the effects of treatment. It is interesting, however,
that the prevalence results are compatible with regions with intermediate
levels of HIV transmission. By intermediate levels of HIV transmission, we
mean regions of the world with HIV/AIDS prevalences ranging from 0.5%
to 1.2%[23]. Note that without the PI class there would be no disease in
the general population and the infection would be restricted to the other
three classes. However, as mentioned before, our model is too schematic to
guarantee that the above conclusion can be extended to any real population.
Note also that in table 1 the ratio between i and Φ, which gives the num-
ber of new cases of HIV infection per unprotected sexual relation with each
new partner. So, for instance, considering the class GIV, our results point
to a risk of acquiring HIV infection of approximately 3.0% per unprotected
sexual contact. This result is of the same order of that reported in the liter-
ature (for instance, in Thailand this risk was estimated to be between 3.1%
and 5.6% [28]).
In order to evaluate the impact of antiretroviral treatment on the inci-
dence and prevalence of HIV infection we simulated the model for values of
K (effectiveness of treatment) ranging from 0 to 3 and ν (intensity of treat-
ment) ranging from 0.05 to 0.5. The impact of antiretroviral treatment on
the incidence and prevalence of HIV infection in each class is shown in figures
4 to 8. Figure 4 shows the effect of antiretroviral treatment on the class rep-
resenting GI (Q = 115, 000). In this class the risk of contracting HIV is very
low, reaching a prevalence without antiretroviral treatment of the order of
0.1%. In fact, this low prevalence is due to the PI individuals, without whom
the disease among the general population would disappear, meaning that for
Q = 115, 000 the infection is below the threshold for its maintenance in the
general population. Figures 4a and 4b show the incidence and prevalence,
respectively, as functions of the intensity of antiretroviral treatment ν for six
levels of effectiveness of antiretroviral treatment K. Note that the infection
drops monotonically with ν for all values of K.
Figure 4a
Figure 4b
Figure 5 shows the effect of antiretroviral treatment on the class rep-
resenting the subpopulation GII (Q = 138, 000). In this class the risk of
contracting HIV is higher than in the GI, described above. Without an-
tiretroviral treatment the prevalence of HIV infection reaches the order of
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2.0%. Figures 5a and 5b show the incidence and prevalence, respectively, as
functions of the intensity of antiretroviral treatment ν for six levels of effec-
tiveness of antiretroviral treatment K. Note that for K = 0.5 the treatment
results in higher prevalence and incidence than in its absence, for all values of
ν. Moreover, both the incidence and the prevalence show an initial increase
with the treatment intensity and a decrease after around υ = 0.15.
Figure 5a
Figure 5b
To understand the phenomenon described above, one should consider the
following: first, a low intensity treatment means that the individuals, on
the average, start to be treated later than with a high intensity treatment;
secondly, starting the treatment implies in reducing the probability of HIV
transmission proportionally to the reduction in the log of viral load due to the
effect of the treatment; finally, treating individuals implies in a longer survival
period, therefore increasing the total number of sexual contacts of those
individuals. Hence, if the effectiveness of the treatment (K) does not reduce
the log of the viral load sufficiently to decrease the probability of transmission
per sexual contact such as to compensate the increased transmission of HIV
due to the higher number of sexual contacts, the total contribution of those
individuals to HIV transmission will increase. Otherwise it will decrease.
This effect repeats itself for the other simulations described below.
Figure 6 shows the effect of antiretroviral treatment on the class repre-
senting the subpopulation of GIII individuals (Q = 145, 000). In this class
the risk of contracting HIV is higher than that of GII, described above.
Without antiretroviral treatment the prevalence of HIV infection reaches the
order of 4.8%. Figures 6a and 6b show the incidence and prevalence, respec-
tively, as functions of the intensity of antiretroviral treatment ν for six levels
of effectiveness of antiretroviral treatment K. Note that, for K = 0.5 the
prevalence and the incidence is greater than without treatment for all values
of ν. For K ≥ 1, the incidence drops monotonically with ν. However, for
K = 1, the prevalence is greater than that without treatment for values of ν
up to approximately 0.8.
Figure 6a
Figure 6b
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Figure 7 shows the effect of antiretroviral treatment on the class rep-
resenting the subpopulation GIV (Q = 155, 000). In this class the risk of
contracting HIV is the highest among all classes considered. Without an-
tiretroviral treatment the prevalence of HIV infection reaches the order of
9%. Figures 7a and 7b show the incidence and prevalence, respectively, as
functions of the intensity of antiretroviral treatment ν for six levels of ef-
fectiveness of antiretroviral treatment K. Note that both the incidence and
the prevalence for K = 0.5 are higher than those without treatment, for all
values of ν. For K = 1 and K = 1.5, the incidence drops monotonically but
the prevalence is greater than that without treatment for small values of ν.
Figure 7a
Figure 7b
Figure 8 shows the weighted average of the incidence (8a) and prevalence
(8b) curves over the entire population. Note that both the incidence and the
prevalence forK = 0.5 are higher than those without treatment, for all values
of ν. For K ≥ 1, both the incidence and prevalence drop monotonically.
Figure 8a
Figure 8b
6 Comments and conclusions
In this paper we presented a very simple model of the steady-state effect of
HAART on HIV incidence and prevalence. The model mimics current treat-
ment guidelines applied in Brazil. However, the model does not intend to fit
the data with any acceptable degree of accuracy since detailed information
necessary are not available. So, this paper intends to provide a conceptual
and mechanistic understanding of the possible long term effects of treatment
on the dynamics of HIV transmission. As mentioned by Anderson [29], one
of the purposes of modelling is to help identifying areas in which better epi-
demiological data is required to refine prediction and improve understanding,
guiding, in a way, field research. We hope our model can be useful in pointing
which parameters should be better determined in future studies.
The model could be extended to allow the calculation of temporal evo-
lution of the effects of treatment on HIV incidence, as we did for rubella
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vaccination in [12]. At the present stage we calculated only steady-state ef-
fects, which is important enough for assessing long term effects of treatment
on trends of HIV dynamics.
One important aspect of the model is that the population was divided
into four compartments according to their sexual activities. We also assumed
another compartment of PIs and we assumed that only they interact with the
other four different model compartments. The PIs were singled out because
they acquire the infection by a different route. It would appear natural to
consider that the risk groups would interact with each other. However, this
would introduce more unknown parameters and, therefore, for simplicity we
considered such an interaction as negligible. Note that this implies that if
an individual from any single risk group, for instance GI, has an unprotected
sexual contact with any other individuals from another group he/she and
his/her stable partner would be considered as belonging to this class.
Our main conclusions are as follows:
1. The disease, according to the model, is almost completely wiped out
when we consider the most effective treatment (K = 3.0) simulated.
This conclusion should be taken with great care since it may be the re-
sult of some ’mathematical pathology’ taken to its extreme. In fact, the
model predicts that under this treatment regime the disease is main-
tained in the population (all four classes) due to the interaction of indi-
viduals from the other classes with PIs. Again, this conclusion should
be taken with caution since, by allowing strong interactions between the
distinct sexual behavior classes the disease might not disappear under
treatment. In addition, note that our simulated treatment represents
the worst scenario (the immediate evolution of complete resistance with
no further alteration in the treatment scheme), while in clinical practice
modifications of treatment schemes should always follows a significant
increase in viraemia.
2. The impact of the treatment on HIV incidence or prevalence depends
on the level of sexual activity of the subpopulations considered, being
more pronounced on the subpopulations with the highest sexual ac-
tivity levels. By impact of treatment we mean the difference between
the pre-treatment level of incidence or prevalence and the equilibrium
attained with the maximum intensity of treatment, ν. This conclusion
is valid only for the most effective treatment scheme, K = 3.0
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3. Inefficient treatment, K < 1.0, can be prejudicial on the subpopulations
with high levels of sexual activity. For instance, in populations with
intermediate levels of sexual activity (Φ = 0.153 years−1), the effect
of inefficient treatment depends on the intensity of treatment, ν, in a
curious way. For ν between 0 and 0.15, there is an increase in both
incidence and prevalence, which then drops thereafter. The reason for
this behavior is explained in the main body of the text.
As a general comment, there are many ways to express the intensity of
transmission of an infection, among which the classical basic reproduction
ratio, R0, the force of infection, λ(a), the incidence and the prevalence. The
basic reproduction ratio is the greatest eigenvalue of the Frechet derivative
with respect to λ(a) of the operator, which is the right hand side of equation
28, calculated at λ(a) = 0 (see [13], [30]). In this paper we calculated the
incidence and the prevalence of HIV as these are the parameters most used
by public health authorities to monitor HIV epidemic.
Finally, since HIV treatment begins late in the second phase (in practice
and in this model), the intensity and diversity of effects that result from
different treatment strategies is another evidence of the importance of the
asymptomatic phase of HIV infection on the spread of the virus. This has
already been pointed out [31], contrasting with former opinions of some in-
fectious disease practitioners and epidemiologists.
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Captions for the figures
Figure 1: Reduction in the mortality by AIDS in the period between
1996 and 2001. The total number of averted deaths summed up to 90,000
patients in this period.
Figure 2: Reduction in the incidence rates in Brazil two years after the
introduction of universal highly active antiretroviral treatment.
Figure 3: (a) Model assumed to describe the natural variation of HIV
viraemia along the natural history of the infection (shaded area). The infec-
tion happens at age between τ and τ +dτ and Lc marks the beginning of full
blown AIDS. (b) Model assumed to describe the natural variation of HIV
viraemia along the natural history of the infection in presence of antiretro-
viral treatment (shaded area). The infection happens at age between τ and
τ +dτ , the treatment begins at age betweenl and l + dl and L′c marks the
beginning of full blown AIDS.
Figure 4: (a) The incidence of HIV in the GI (general population) group
as a function of the treatment intensity rate ν for several levels of effectiveness
of antiretroviral treatment K. (b) The prevalence of HIV in the GI (general
population) group as a function of the treatment intensity rate ν for several
levels of effectiveness of antiretroviral treatment K.
Figure 5: (a) The incidence of HIV in the class representing the sub-
population of GII (promiscuous heterosexuals) group, as a function of the
treatment intensity rate ν for several levels of effectiveness of antiretroviral
treatment K. (b) The prevalence of HIV in the class representing the sub-
population GII (promiscuous heterosexuals), as a function of the treatment
intensity rate ν for several levels of effectiveness of antiretroviral treatment
K.
Figure 6: (a) The incidence of HIV in the class representing the sub-
population GIII (male homosexuals), as a function of the treatment intensity
rate ν for several levels of effectiveness of antiretroviral treatment K. (b) The
prevalence of HIV in the class representing the sub-population GIII (male
homosexuals), as a function of the treatment intensity rate ν for several levels
of effectiveness of antiretroviral treatment K.
Figure 7: (a) The incidence of HIV in the class representing the sub-
population GIV (sex workers) and their clients, as a function of the treatment
intensity rate ν for several levels of effectiveness of antiretroviral treatment
K. (b) The prevalence of HIV in the class representing the sub-population
GIV (sex workers) and their clients, as a function of the treatment intensity
28
rate ν for several levels of effectiveness of antiretroviral treatment K.
Figure 8:(a) The incidence of HIV in the population average as a func-
tion of the treatment intensity rate ν for several levels of effectiveness of
antiretroviral treatment K. (b) The prevalence of HIV in the population
average as a function of the treatment intensity rate ν for several levels of
effectiveness of antiretroviral treatment K.
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